<DOC>
	<DOCNO>NCT00238082</DOCNO>
	<brief_summary>This investigator-sponsored research study evaluate treatment HFA-134a beclomethasone ( QVAR ) effect peripheral ( outer ) airway inflammation airway `` remodel '' scar subject COPD . Approximately 20 subject COPD participate approximately 7 week , 10 receive active ( BDP ) inhaler HFA-134a 10 receive placebo .</brief_summary>
	<brief_title>The Effect QVAR Lung Functioning Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>COPD diagnosis FEV1/FVC &lt; 70 % FEV1 5080 % predict Albuterol response &lt; 12 % &lt; 200mL methacholine PC20 &gt; 8mg/mL RV &gt; 120 % predict DLCO &lt; 80 % smoker nonsmoker Lower age limit 45 year Asthma Other chronic airway parenchymal lung disease Other comorbid illness ( include limit DM , MI CADrelated intervention 6 month , neurologic disease , syncope ) Use steroid ( oral , IV , nasal , pulmonary ) within 12 week Use theophylline , leukotriene modifier within 12 week Use longacting betaagonists ( formoterol , salmeterol ) anticholinergic ( tiotropium )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic Bronchitis</keyword>
</DOC>